Loh Kah Poh, Tsang Mazie, LeBlanc Thomas W, Back Anthony, Duberstein Paul R, Mohile Supriya Gupta, Epstein Ronald M, Klepin Heidi D, Becker Michael W, El-Jawahri Areej, Lee Stephanie J
James P. Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY.
Helen Diller Family Comprehensive Cancer Center, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA.
Blood Adv. 2020 Nov 10;4(21):5492-5500. doi: 10.1182/bloodadvances.2020003044.
Understanding decisional involvement and information preferences in patients with hematologic malignancies may help to optimize physician-patient communication about treatment decisions and align the decision-making processes with patients' preferences. We described and examined factors associated with preferences of patients with hematologic malignancies for decisional involvement, information sources, and presentation of information. In a multicenter observational study, we recruited 216 patients with hematologic malignancies of any stage from September 2003 to June 2007. Patients were asked about their decisional involvement preferences (Control Preferences Scale), information sources (including most useful source of information), and preferences for their oncologists' presentation of treatment success information. We used multivariate logistic regressions to identify factors associated with decisional involvement preferences and usefulness of information sources (physicians vs nonphysicians). Patient-directed, shared, and physician-directed approaches were preferred in 34%, 38%, and 28% of patients, respectively. Physicians and computer/Internet were the most common information sources; 42% perceived physicians as the most useful source. On multivariate analysis, patients with less than a college education (vs postgraduate education) were less likely to perceive their physician as the most useful source (adjusted odds ratio [AOR], 0.46; 95% confidence interval (CI), 0.21-1.00), whereas patients with acute leukemia (vs other blood cancers) were more likely to perceive their physician as the most useful source (AOR, 2.49; 95% CI, 1.07-5.80). In terms of communicating treatment success rates, 70% preferred ≥1 method(s), and 88% preferred presentation in percentages. Our study suggests that decisional involvement and information preferences vary and should be assessed explicitly as part of each decision-making encounter.
了解血液系统恶性肿瘤患者的决策参与度和信息偏好,可能有助于优化医患之间关于治疗决策的沟通,并使决策过程与患者偏好保持一致。我们描述并研究了与血液系统恶性肿瘤患者在决策参与度、信息来源及信息呈现方面的偏好相关的因素。在一项多中心观察性研究中,我们于2003年9月至2007年6月招募了216例处于任何阶段的血液系统恶性肿瘤患者。询问患者关于他们的决策参与度偏好(控制偏好量表)、信息来源(包括最有用的信息来源)以及他们对肿瘤医生呈现治疗成功率信息的偏好。我们使用多变量逻辑回归来确定与决策参与度偏好及信息来源(医生与非医生)的有用性相关的因素。分别有34%、38%和28%的患者偏好患者主导、共同决策和医生主导的方法。医生和计算机/互联网是最常见的信息来源;42%的患者认为医生是最有用的信息来源。多变量分析显示,教育程度低于大学(与研究生教育相比)的患者将医生视为最有用信息来源的可能性较小(调整优势比[AOR]为0.46;95%置信区间[CI]为0.21 - 1.00),而急性白血病患者(与其他血液癌症相比)将医生视为最有用信息来源的可能性更大(AOR为2.49;95% CI为1.07 - 5.80)。在传达治疗成功率方面,70%的患者偏好≥1种方法,88%的患者偏好以百分比形式呈现。我们的研究表明,决策参与度和信息偏好各不相同,应在每次决策过程中明确进行评估。